Targeting CaN: An Exciting Research Topic (P16683)

Target Name: Protein Phosphatase 2B

NCBI ID: P16683

Protein Phosphatase 2B

Other Name(s): CaN | PP2B | Calcineurin | PP-2B

Targeting CaN: An Exciting Research Topic

Protein phosphatase 2B (CaN) is a protein that plays a crucial role in cellular signaling. It is a key enzyme in the PI3K/Akt signaling pathway, which is involved in various cellular processes such as cell growth, differentiation, and survival. Unfortunately, CaN has also been implicated in the development and progression of various diseases, including cancer. As a result, targeting CaN has become an attractive research topic in recent years.

CaN is a protein that is expressed in various cell types, including neurons, macrophages, and breast cells. It is a key enzyme in the PI3K/Akt signaling pathway, which is a critical pathway involved in the regulation of cellular signaling. The PI3K/Akt signaling pathway is a complex signaling pathway that is involved in the regulation of various cellular processes, including cell growth, differentiation, and survival.

CaN is a protein that is highly conserved across various species, including humans. It has a molecular weight of approximately 180 kDa and is composed of two distinct subunits, alpha-subunit and beta-subunit. The alpha-subunit has a molecular weight of approximately 90 kDa and is responsible for catalyzing the phosphorylation of the protein. The beta-subunit has a molecular weight of approximately 90 kDa and is responsible for regulating the activity of the alpha-subunit.

CaN is involved in the regulation of various cellular processes, including cell growth, differentiation, and survival. It is a key enzyme in the PI3K/Akt signaling pathway, which is involved in the regulation of cellular signaling. The PI3K/Akt signaling pathway is a complex signaling pathway that is involved in the regulation of various cellular processes, including cell growth, differentiation, and survival.

CaN has been implicated in the development and progression of various diseases, including cancer. For example, studies have shown that CaN levels are often elevated in various types of cancer, including breast cancer. Additionally, CaN has been shown to promote the growth and survival of various cancer cells.

Targeting CaN has become an attractive research topic in recent years. One way to target CaN is through the use of small molecules, such as inhibitors. These inhibitors can be used to inhibit the activity of CaN and prevent it from promoting the growth and survival of cancer cells. Additionally, researchers can also use antibodies to target CaN and prevent it from interacting with other proteins.

Another way to target CaN is through the use of drugs that target the PI3K/Akt signaling pathway. These drugs work by inhibiting the activity of the PI3K/Akt signaling pathway, which will prevent CaN from functioning. As a result, targeting CaN has become an attractive research topic in recent years, and the development of drugs that target CaN is an promising area of research.

In conclusion, Protein phosphatase 2B (CaN) is a protein that plays a crucial role in cellular signaling. It is a key enzyme in the PI3K/Akt signaling pathway and has been implicated in the development and progression of various diseases, including cancer. As a result, targeting CaN has become an attractive research topic in recent years and the development of drugs that target CaN is an promising area of research. Further studies are needed to understand the full role of CaN in cellular signaling and to develop effective drugs that target CaN.

Protein Name: Protein Phosphatase 2B

The "Protein Phosphatase 2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Protein Phosphatase 2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets